Study identifier:D4080C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2011-001337-16
CTIS identifier:N/A
A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Biomarkers of AZD3839 Including an Open-label Food Effect Group in Healthy Male and Female Volunteers of Non-childbearing Potential
Alzheimer's disease, Safety, Healthy Volunteers
Phase 1
Yes
AZD3839, AZD3839 Placebo
All
72
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD3839 Oral Treatment | Drug: AZD3839 Single Oral Dose |
Placebo Comparator: AZD3839 Placebo Oral Treatment | Drug: AZD3839 Placebo Single Oral Dose |